NL-OMON33365尚未招募不适用
Quantitative FDG-PET/CT of primary bladder cancer - Quantitative FDG-PET/CT of primary bladder cancer
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histology proven bladder cancer
- •2. Untreated, primary evaluation
- •3. cT2-4 Nx Mx
排除标准
- •1. Contra-indication for bladder catheter
- •2. Pregnancy or breastfeeding
- •3. Age < 18 years
- •4. Restricted water intake
研究者
相似试验
进行中（未招募）
2 期
FDG-PET/CT alters treatment in node-positive penile cancerPenile cancerCancerISRCTN49141161Skåne University Hospital100
尚未招募
Unknown
To prove diagnostic accuracy of PET/CT in all cancer penis patients having groin involvement clinically. If we can prove diagnostic accuracy of the pelvic lymph node involvement, then we can avoid pelvic surgery which will be reduce complications associated with surgery.CTRI/2022/03/041401IRB committee CMC Vellore
进行中（未招募）
不适用
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001819-30-DESanochemia Pharmazeutika AG220
进行中（未招募）
不适用
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001819-30-ATSanochemia Pharmazeutika AG220
已完成
2 期
Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy(Hypericin PDD)C67Malignant neoplasm of bladderDRKS00003324Sanochemia Pharmazeutika AG227